From the mid-19th century until today, life expectancy at birth in the United States has roughly doubled, from 39.4 years in 1850 to 79.6 years in 2025. It is estimated that life expectancy in the U.S. began its upward trajectory in the 1880s, largely driven by the decline in infant and child mortality through factors such as vaccination programs, antibiotics, and other healthcare advancements. Improved food security and access to clean water, as well as general increases in living standards (such as better housing, education, and increased safety) also contributed to a rise in life expectancy across all age brackets. There were notable dips in life expectancy; with an eight year drop during the American Civil War in the 1860s, a seven year drop during the Spanish Flu empidemic in 1918, and a 2.5 year drop during the Covid-19 pandemic. There were also notable plateaus (and minor decreases) not due to major historical events, such as that of the 2010s, which has been attributed to a combination of factors such as unhealthy lifestyles, poor access to healthcare, poverty, and increased suicide rates, among others. However, despite the rate of progress slowing since the 1950s, most decades do see a general increase in the long term, and current UN projections predict that life expectancy at birth in the U.S. will increase by another nine years before the end of the century.

This statistic shows the average life expectancy in North America for those born in 2022, by gender and region. In Canada, the average life expectancy was 80 years for males and 84 years for females.

Life expectancy in North America

Of those considered in this statistic, the life expectancy of female Canadian infants born in 2021 was the longest, at 84 years. Female infants born in America that year had a similarly high life expectancy of 81 years. Male infants, meanwhile, had lower life expectancies of 80 years (Canada) and 76 years (USA).

Compare this to the worldwide life expectancy for babies born in 2021: 75 years for women and 71 years for men. Of continents worldwide, North America ranks equal first in terms of life expectancy of (77 years for men and 81 years for women). Life expectancy is lowest in Africa at just 63 years and 66 years for males and females respectively. Japan is the country with the highest life expectancy worldwide for babies born in 2020.

Life expectancy is calculated according to current mortality rates of the population in question. Global variations in life expectancy are caused by differences in medical care, public health and diet, and reflect global inequalities in economic circumstances. Africa’s low life expectancy, for example, can be attributed in part to the AIDS epidemic. In 2019, around 72,000 people died of AIDS in South Africa, the largest amount worldwide. Nigeria, Tanzania and India were also high on the list of countries ranked by AIDS deaths that year. Likewise, Africa has by far the highest rate of mortality by communicable disease (i.e. AIDS, neglected tropics diseases, malaria and tuberculosis).

In 2024, the average life expectancy in the world was 71 years for men and 76 years for women. The lowest life expectancies were found in Africa, while Oceania and Europe had the highest. What is life expectancy?Life expectancy is defined as a statistical measure of how long a person may live, based on demographic factors such as gender, current age, and most importantly the year of their birth. The most commonly used measure of life expectancy is life expectancy at birth or at age zero. The calculation is based on the assumption that mortality rates at each age were to remain constant in the future. Life expectancy has changed drastically over time, especially during the past 200 years. In the early 20th century, the average life expectancy at birth in the developed world stood at 31 years. It has grown to an average of 70 and 75 years for males and females respectively, and is expected to keep on growing with advances in medical treatment and living standards continuing. Highest and lowest life expectancy worldwide Life expectancy still varies greatly between different regions and countries of the world. The biggest impact on life expectancy is the quality of public health, medical care, and diet. As of 2022, the countries with the highest life expectancy were Japan, Liechtenstein, Switzerland, and Australia, all at 84–83 years. Most of the countries with the lowest life expectancy are mostly African countries. The ranking was led by the Chad, Nigeria, and Lesotho with 53–54 years.

Life expectancy at birth, female (years) in United States was reported at 81.1 years in 2023, according to the World Bank collection of development indicators, compiled from officially recognized sources. United States - Life expectancy at birth, female (years) - actual values, historical data, forecasts and projections were sourced from the World Bank on November of 2025.

In 2023, a woman in the United States aged 65 years could expect to live another **** years on average. This number decreased in the years 2020 and 2021, after reaching a high of **** years in 2019. Nevertheless, the life expectancy of a woman aged 65 years in the United States is still higher than that of a man of that age. In 2023, a man aged 65 years could be expected to live another 18.2 years on average. Why has the life expectancy in the U.S. declined? Overall, life expectancy in the United States has declined in recent years. In 2019, the life expectancy for U.S. women was **** years, but by 2023 it had decreased to **** years. Likewise, the life expectancy for men decreased from **** years to **** years in the same period. The biggest contributors to this decline in life expectancy are the COVID-19 pandemic and the opioid epidemic. Although deaths from the COVID-19 pandemic have decreased significantly since 2022, deaths from opioid overdose continue to increase, reaching all-time highs in 2022. The leading causes of death among U.S. women The leading causes of death among women in the United States in 2022 were heart disease, cancer, stroke, and COVID-19. That year, heart disease and cancer accounted for a combined **** percent of all deaths among women, while around *** percent of deaths were due to COVID-19. The overall leading causes of death in the United States generally reflect the leading causes among women, with some slight variations. For example, Alzheimer’s disease is the ***** leading cause of death among women but the ******* leading cause of death overall in the United States.

Number of deaths and mortality rates, by age group, sex, and place of residence, 1991 to most recent year.

The average life span for a person born with hypoplastic left heart syndrome (HLHS) in the United States was around 30 years as of 2024. Hypoplastic left heart syndrome (HLHS) is a rare congenital heart defect. Treatment may include multiple surgeries and even a heart transplant. This statistic shows the average life expectancy for select complex congenital heart defects in the U.S. as of 2024.

Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.

This file contains COVID-19 death counts, death rates, and percent of total deaths by jurisdiction of residence. The data is grouped by different time periods including 3-month period, weekly, and total (cumulative since January 1, 2020). United States death counts and rates include the 50 states, plus the District of Columbia and New York City. New York state estimates exclude New York City. Puerto Rico is included in HHS Region 2 estimates. Deaths with confirmed or presumed COVID-19, coded to ICD–10 code U07.1. Number of deaths reported in this file are the total number of COVID-19 deaths received and coded as of the date of analysis and may not represent all deaths that occurred in that period. Counts of deaths occurring before or after the reporting period are not included in the file. Data during recent periods are incomplete because of the lag in time between when the death occurred and when the death certificate is completed, submitted to NCHS and processed for reporting purposes. This delay can range from 1 week to 8 weeks or more, depending on the jurisdiction and cause of death. Death counts should not be compared across states. Data timeliness varies by state. Some states report deaths on a daily basis, while other states report deaths weekly or monthly. The ten (10) United States Department of Health and Human Services (HHS) regions include the following jurisdictions. Region 1: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont; Region 2: New Jersey, New York, New York City, Puerto Rico; Region 3: Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, West Virginia; Region 4: Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee; Region 5: Illinois, Indiana, Michigan, Minnesota, Ohio, Wisconsin; Region 6: Arkansas, Louisiana, New Mexico, Oklahoma, Texas; Region 7: Iowa, Kansas, Missouri, Nebraska; Region 8: Colorado, Montana, North Dakota, South Dakota, Utah, Wyoming; Region 9: Arizona, California, Hawaii, Nevada; Region 10: Alaska, Idaho, Oregon, Washington. Rates were calculated using the population estimates for 2021, which are estimated as of July 1, 2021 based on the Blended Base produced by the US Census Bureau in lieu of the April 1, 2020 decennial population count. The Blended Base consists of the blend of Vintage 2020 postcensal population estimates, 2020 Demographic Analysis Estimates, and 2020 Census PL 94-171 Redistricting File (see https://www2.census.gov/programs-surveys/popest/technical-documentation/methodology/2020-2021/methods-statement-v2021.pdf). Rates are based on deaths occurring in the specified week/month and are age-adjusted to the 2000 standard population using the direct method (see https://www.cdc.gov/nchs/data/nvsr/nvsr70/nvsr70-08-508.pdf). These rates differ from annual age-adjusted rates, typically presented in NCHS publications based on a full year of data and annualized weekly/monthly age-adjusted rates which have been adjusted to allow comparison with annual rates. Annualization rates presents deaths per year per 100,000 population that would be expected in a year if the observed period specific (weekly/monthly) rate prevailed for a full year. Sub-national death counts between 1-9 are suppressed in accordance with NCHS data confidentiality standards. Rates based on death counts less than 20 are suppressed in accordance with NCHS standards of reliability as specified in NCHS Data Presentation Standards for Proportions (available from: https://www.cdc.gov/nchs/data/series/sr_02/sr02_175.pdf.).

This dataset contains counts of deaths for California counties based on information entered on death certificates. Final counts are derived from static data and include out-of-state deaths to California residents, whereas provisional counts are derived from incomplete and dynamic data. Provisional counts are based on the records available when the data was retrieved and may not represent all deaths that occurred during the time period. Deaths involving injuries from external or environmental forces, such as accidents, homicide and suicide, often require additional investigation that tends to delay certification of the cause and manner of death. This can result in significant under-reporting of these deaths in provisional data.

The final data tables include both deaths that occurred in each California county regardless of the place of residence (by occurrence) and deaths to residents of each California county (by residence), whereas the provisional data table only includes deaths that occurred in each county regardless of the place of residence (by occurrence). The data are reported as totals, as well as stratified by age, gender, race-ethnicity, and death place type. Deaths due to all causes (ALL) and selected underlying cause of death categories are provided. See temporal coverage for more information on which combinations are available for which years.

The cause of death categories are based solely on the underlying cause of death as coded by the International Classification of Diseases. The underlying cause of death is defined by the World Health Organization (WHO) as "the disease or injury which initiated the train of events leading directly to death, or the circumstances of the accident or violence which produced the fatal injury." It is a single value assigned to each death based on the details as entered on the death certificate. When more than one cause is listed, the order in which they are listed can affect which cause is coded as the underlying cause. This means that similar events could be coded with different underlying causes of death depending on variations in how they were entered. Consequently, while underlying cause of death provides a convenient comparison between cause of death categories, it may not capture the full impact of each cause of death as it does not always take into account all conditions contributing to the death.

This dataset contains counts of deaths for California as a whole based on information entered on death certificates. Final counts are derived from static data and include out-of-state deaths to California residents, whereas provisional counts are derived from incomplete and dynamic data. Provisional counts are based on the records available when the data was retrieved and may not represent all deaths that occurred during the time period. Deaths involving injuries from external or environmental forces, such as accidents, homicide and suicide, often require additional investigation that tends to delay certification of the cause and manner of death. This can result in significant under-reporting of these deaths in provisional data.

The final data tables include both deaths that occurred in California regardless of the place of residence (by occurrence) and deaths to California residents (by residence), whereas the provisional data table only includes deaths that occurred in California regardless of the place of residence (by occurrence). The data are reported as totals, as well as stratified by age, gender, race-ethnicity, and death place type. Deaths due to all causes (ALL) and selected underlying cause of death categories are provided. See temporal coverage for more information on which combinations are available for which years.

The cause of death categories are based solely on the underlying cause of death as coded by the International Classification of Diseases. The underlying cause of death is defined by the World Health Organization (WHO) as "the disease or injury which initiated the train of events leading directly to death, or the circumstances of the accident or violence which produced the fatal injury." It is a single value assigned to each death based on the details as entered on the death certificate. When more than one cause is listed, the order in which they are listed can affect which cause is coded as the underlying cause. This means that similar events could be coded with different underlying causes of death depending on variations in how they were entered. Consequently, while underlying cause of death provides a convenient comparison between cause of death categories, it may not capture the full impact of each cause of death as it does not always take into account all conditions contributing to the death.

This dataset reports the daily reported number of the 7-day moving average rates of Deaths involving COVID-19 by vaccination status and by age group. Learn how the Government of Ontario is helping to keep Ontarians safe during the 2019 Novel Coronavirus outbreak. Effective November 14, 2024 this page will no longer be updated. Information about COVID-19 and other respiratory viruses is available on Public Health Ontario’s interactive respiratory virus tool: https://www.publichealthontario.ca/en/Data-and-Analysis/Infectious-Disease/Respiratory-Virus-Tool Data includes: * Date on which the death occurred * Age group * 7-day moving average of the last seven days of the death rate per 100,000 for those not fully vaccinated * 7-day moving average of the last seven days of the death rate per 100,000 for those fully vaccinated * 7-day moving average of the last seven days of the death rate per 100,000 for those vaccinated with at least one booster ##Additional notes As of June 16, all COVID-19 datasets will be updated weekly on Thursdays by 2pm. As of January 12, 2024, data from the date of January 1, 2024 onwards reflect updated population estimates. This update specifically impacts data for the 'not fully vaccinated' category. On November 30, 2023 the count of COVID-19 deaths was updated to include missing historical deaths from January 15, 2020 to March 31, 2023. CCM is a dynamic disease reporting system which allows ongoing update to data previously entered. As a result, data extracted from CCM represents a snapshot at the time of extraction and may differ from previous or subsequent results. Public Health Units continually clean up COVID-19 data, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes and current totals being different from previously reported cases and deaths. Observed trends over time should be interpreted with caution for the most recent period due to reporting and/or data entry lags. The data does not include vaccination data for people who did not provide consent for vaccination records to be entered into the provincial COVaxON system. This includes individual records as well as records from some Indigenous communities where those communities have not consented to including vaccination information in COVaxON. “Not fully vaccinated” category includes people with no vaccine and one dose of double-dose vaccine. “People with one dose of double-dose vaccine” category has a small and constantly changing number. The combination will stabilize the results. Spikes, negative numbers and other data anomalies: Due to ongoing data entry and data quality assurance activities in Case and Contact Management system (CCM) file, Public Health Units continually clean up COVID-19, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes, negative numbers and current totals being different from previously reported case and death counts. Public Health Units report cause of death in the CCM based on information available to them at the time of reporting and in accordance with definitions provided by Public Health Ontario. The medical certificate of death is the official record and the cause of death could be different. Deaths are defined per the outcome field in CCM marked as “Fatal”. Deaths in COVID-19 cases identified as unrelated to COVID-19 are not included in the Deaths involving COVID-19 reported. Rates for the most recent days are subject to reporting lags All data reflects totals from 8 p.m. the previous day. This dataset is subject to change.

Overview

The Global Women’s Health Market is expected to reach US$ 66 Billion by 2033, rising from US$ 41.3 Billion in 2023, according to industry estimates. The market is projected to grow at a CAGR of 4.8% from 2024 to 2033. Growth is driven by shifts in population demographics and the rising focus on preventive care. According to United Nations projections, the population aged 65 years and older is likely to reach 2.2 billion by the late 2070s. This leads to a higher need for bone health, cardiometabolic services, cancer screening, and menopause care.

Noncommunicable diseases are placing a major burden on health systems. WHO reports confirm that NCDs caused 43 million deaths in 2021, which accounted for three quarters of all non-pandemic deaths. Notably, 18 million deaths occurred before age 70. The dominance of heart disease, diabetes, respiratory illnesses, and cancer strengthens demand for integrated primary and specialized care designed specifically for women. These conditions emphasize prevention, early diagnosis, and long-term disease management solutions.

Maternal and reproductive health needs are also significant. Study by UN agencies shows 287,000 maternal deaths in 2020, with limited progress since 2016. This situation supports investment in trained workforce, emergency obstetric care, and improved supply chains. Moreover, WHO indicates that among 1.9 billion women of reproductive age in 2021, 1.1 billion required family planning. 874 million used modern contraception, while 164 million still had unmet needs. For instance, UN DESA notes the rise in unmet need from 147 million in 1990 to current levels, signaling strong demand for accessible services.

Infertility care is advancing rapidly. WHO estimates note that 17.5% of adults, or one in six individuals, experience infertility. Similar prevalence is seen across all income regions. This trend expands opportunities in fertility diagnostics, assisted reproductive technologies, and supportive financing models. Preventive services are also expanding. WHO and UNICEF data confirm that adolescent girls receiving at least one HPV vaccine dose grew from 20% in 2022 to 27% in 2023. WHO’s 2025 update indicates 31% global first-dose coverage, strengthening screening and treatment service demand.

Cancer and mental health represent long-term growth areas. According to IARC, breast cancer remains the world’s most commonly diagnosed cancer, supporting continued investments in imaging, pathology, and survivorship care. WHO highlights that depression is 1.5 times more common in women, and more than 10% of pregnant women and 13% after childbirth experience mental disorders. Policy support is increasing as well. For example, ILO/World Bank data show 48.7% female labor force participation in 2023, encouraging workplace benefits. National strategies, such as England’s Women’s Health Strategy, further enhance attention to midlife health and menopause services.

According to Cognitive Market Research, the Cardiovascular Devices Market Size was USD XX Billion in 2024 and is set to achieve a market size of USD XX Billion by the end of 2033 growing at a CAGR of XX% from 2025 to 2033.

North America held largest share of XX% in the year 2024 
Europe held share of XX% in the year 2024 
Asia-Pacific held significant share of XX% in the year 2024 
South America held significant share of XX% in the year 2024
Middle East and Africa held significant share of XX% in the year 2024 

Market Dynamics of the Cardiovascular Devices Market

Key Drivers for the Cardiovascular Devices Market

Rising in cardiovascular diseases prevalence fuels the cardiovascular devices market

The cardiovascular disorders are the group of medical condition where it affects heart and blood vessels, encompassing various diseases and disorder that affects on the circulatory system. The cardiac devices help to maintain the regular heart function and blood flow in patients with weak improper function of heart. The global cardiac device market shows significant growth, largely driven by increase in prevalence of heart disease. The cardiovascular disease treatment is costly in terms of healthcare services. Now the conditions like coronary artery disease and heart failure are becoming increasingly prevalent, so there is increase in demand of coronary stents and crucial devices which are used to treat the cardiovascular diseases. Also, the global population increases and continues to age the incidence of chronic heart condition is expected to rise. This demographic condition is shift further and results in growing need of cardiovascular devices that can treat the wide range of heart diseases.

For instance, according to centers for disease control and prevention (CDC) in the United States heart diseases is the major cause of death for both men and women and people of most racial and ethnic groups. They said that one person dies every 33 seconds from cardiovascular disease. In 2022, 702,880 people died from heart disease. That is equivalent to 1 in every 5 deaths

(Source -https://www.cdc.gov/heart-disease/index.html)

Thus, due to the rising patients in cardiovascular disease segment and the advancement in technology boosts the cardiovascular devices market. Rising awareness of health also helps to drive this market.

The rise in healthcare expenditure drives the Cardiovascular Devices Market

Globally the health awareness is increasing vastly countries monitor their health of the population related to cardiac health preferably. They also focus on the expansion of healthcare expenditure where the people also now get aware about their health. The advancement in technology of medical devices increases the patient convenience and now they can get treatment and monitor their health more effectively. Each country now spends on their healthcare expenditure to provide healthcare service to all needy people who cannot afford the costly devices. For instance, U.S. health expenditure grew by 4.1% in 2022 to $4.5 trillion or $13,493 per capita. This rate of growth is similar to pre-pandemic levels (4.1% in 2019). While government expenditure to contain the pandemic resulted in significant growth in NHE, these expenditures fell sharply in 2021 while use of medical goods and services recovered. By 2022, overall trends in health expenditure more closely approximated that of the pre-pandemic era.

(Source - https://www.ama-assn.org/about/research/trends-health-care-spending)

The market for cardiovascular devices is expected to grow as a result of rising healthcare costs. The total amount spent on healthcare-related services, goods, and activities over a given time period usually at the individual, community, national, or international level is referred to as healthcare expenditures. Adoption of cutting-edge cardiovascular technologies and devices is made possible by increased healthcare spending, which improves patient outcomes and care. For Instance, in Europe the spending on cardiovascular disease is greater than the spending done in Germany. CVD is estimated to cost the EU €282 billion annually, with health and long-term care accounting for €155 billion (55%), equaling 11% of EU-health expenditure. Productivity losses accounted for 17% (€48 billion), whereas informal care costs were €79 billion (28%). CVD ...

According to Cognitive Market Research, the Global Heparin Market Size is USD XX Million in 2024 and is set to achieve a market size of USD XX Million by the end of 2033 growing at a CAGR of XX% from 2024 to 2033.

North America held largest share of XX% in the year 2024 
Europe held share of XX% in the year 2024 
Asia-Pacific held significant share of XX% in the year 2024 
South America held significant share of XX% in the year 2024
Middle East and Africa held significant share of XX% in the year 2024 

Market Dynamics of Heparin Market

Key Drivers for Heparin Market

Increasing Prevalence of Cardiovascular Diseases is inflating the heparin market.

Chronic blood diseases cases are increasing exponentially and are expected to propel the global antiplatelet drugs market. Chronic disease prevalence increase is due to drive the market. The increase in the incidence of cardiovascular diseases is one of the key drivers of the growth rate of the antiplatelet drugs market. Cardiovascular disease is the leading cause of mortality in both developed and developing economies.

It is estimated by the Centers for Disease Control and Prevention (CDC) that more than 8,00,000 people in the United States pass away every year due to stroke and other cardiovascular diseases. For instance, a World Health Organization (WHO) study has reported that cardiovascular diseases (CVDs) are responsible for approximately 31% of total patient deaths every year. For instance, in 2022, as noted in a National Library of Medicine study, cardiovascular diseases (CVD) were responsible for approximately 19.8 million deaths globally, necessitating the effective treatment of heparin in controlling thrombosis and mitigating mortality rates of CVD-related complications. The increasing rate of CVDs is a major factor behind the need for heparin: Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is a major cause of cardiovascular mortality worldwide. VTE risk doubles every decade after the age of 40, and is also very high among inpatients, with the incidence of 10 to 20 cases per 1,000 admissions. Atrial fibrillation, a prevalent cardiac arrhythmia, occurs in an estimated 12.1 million Americans by 2030, and this boosts the demand for anticoagulant drugs such as heparin. These highlights the imperative function of heparin in treating and preventing cardiovascular disease-related complications, thus fueling market expansion.

Rising number of geriatric populations increases CVD which in turn increases the usage of heparin and the market is expanding.

Growing geriatric population globally is expected to support heparin drugs demand since this group is susceptible to heart diseases. The population of individuals over 65 years is expected to double in the future years. The old-aged individuals are susceptible to many chronic diseases like cardiovascular diseases, which can encourage the demand for heparin drugs globally. There were approximately 382 million aged people, aged 60 years and older, in the world in 2017 and it is projected to grow to 2.1 billion by 2050, as per the United Nations. Older adults with cardiovascular disease (CVD) often face the challenge of managing multiple chronic or multimorbid conditions, leading to a significant drug burden that complicates their treatment. With the prevalence of multimorbidity ranging from 30% to 83% in individuals aged 65 and older, cardiovascular comorbidities are frequently reported as the most common combination of chronic diseases. This situation is further exacerbated by issues such as functional decline and complex geriatric syndromes (GSs), which are major concerns in the management of this population. Notably, polypharmacy, defined as the simultaneous use of five or more medications, affects 26.3% to 40% of older adults, with excessive polypharmacy impacting around 10%. The incidence of polypharmacy can reach alarming rates, with studies indicating a 53% to 87% incidence over three years. The presence of geriatric syndromes, which can affect 10% to 60% of older adults, significantly contributes to declines in functional status and quality of life, increased hospital admissions, and higher mortality rates. Additionally, frailty, characterized by a reduced physiological reserve and increased vulnerability to stressors, affects 10% of older adults, with rates as high as 60% in those with severe ...

In 2024, about **** million deaths were reported in the United States. This reflected a slight decrease from the previous year, and an ** percent decrease from the peak of the COVID-19 pandemic in 2020.

The graph displays the number of car accident fatalities by gender in the United States from 2010 to 2022. The x-axis represents the years, labeled from '10 to '22, while the y-axis indicates the number of fatalities. Each year includes data points for both males and females. Male fatalities range from a low of 22,937 in 2011 to a high of 30,964 in 2021. Female fatalities vary between 9,463 in 2014 and 12,135 in 2021. The data consistently shows that male fatalities are higher than female fatalities each year. There is a noticeable upward trend in fatalities for both genders in the later years, particularly in 2020 and 2021.

The total life expectancy at birth in the United States stood at 78.39 years in 2023. Between 1960 and 2023, the life expectancy at birth rose by 8.62 years, though the increase followed an uneven trajectory rather than a consistent upward trend.

In the United States in 2021, the death rate was highest among those aged 85 and over, with about 17,190.5 men and 14,914.5 women per 100,000 of the population passing away. For all ages, the death rate was at 1,118.2 per 100,000 of the population for males, and 970.8 per 100,000 of the population for women. The death rate Death rates generally are counted as the number of deaths per 1,000 or 100,000 of the population and include both deaths of natural and unnatural causes. The death rate in the United States had pretty much held steady since 1990 until it started to increase over the last decade, with the highest death rates recorded in recent years. While the birth rate in the United States has been decreasing, it is still currently higher than the death rate. Causes of death There are a myriad number of causes of death in the United States, but the most recent data shows the top three leading causes of death to be heart disease, cancers, and accidents. Heart disease was also the leading cause of death worldwide.

A global phenomenon, known as the demographic transition, has seen life expectancy from birth increase rapidly over the past two centuries. In pre-industrial societies, the average life expectancy was around 24 years, and it is believed that this was the case throughout most of history, and in all regions. The demographic transition then began in the industrial societies of Europe, North America, and the West Pacific around the turn of the 19th century, and life expectancy rose accordingly. Latin America was the next region to follow, before Africa and most Asian populations saw their life expectancy rise throughout the 20th century.